RNA sequencing transformed: Oxford Nanopore introduces new cDNA Sequencing Kits
Oxford Nanopore has launched new ‘109’ cDNA Kits for its real-time, scalable sequencing technology. The new kits provide high throughput whilst generating complete sequences of full-length cDNA strands, with a low input option of just 1ng PolyA+ RNA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190204005413/en/
The new cDNA sequencing method enables users to sequence whole transcriptomes to high coverage on a single MinION flow cell (10-15 million reads x full length transcripts), with substantially higher throughput capabilities on PromethION (more than 60 million reads x full length transcripts per flow cell), or smaller, rapid assays on Flongle. This facilitates new biological insights across a diverse range of applications.
Full-length, well-characterised cDNA transcripts for scientific research, health and industry
Oxford Nanopore’s new long-read cDNA sequencing solutions allow researchers to sequence millions of whole transcripts end-to-end in single reads. This enables users to simultaneously perform accurate isoform-level transcriptome characterisation, and differential gene expression profiling without any of the compromises on cost, quantitation, computational or workflow complexity required to achieve this on other short or long read sequencing platforms.
Deeper insight into the dynamics of the transcriptome are critical in enabling researchers across a broad range of fields to understand how the stable DNA ‘code’ of an organism is interpreted at a given moment in time. In healthcare, the identification of differentially spliced isoforms and fusion transcripts can inform disease diagnosis and treatment. RNA sequencing also provides a rapid, effective method of virus identification, and also has applications in environmental and agricultural science.
Jonathan Gӧke from the Genome Institute of Singapore said:
“We are working on identification of alternative gene isoforms and fusion genes in cancer, and the ability to generate reads that span the entire RNA can make a big difference. With nanopore long read cDNA sequencing kits we obtain a much more detailed view of which transcripts are generated."
Anthony Bayega from McGill University said:
“Nanopore cDNA Sequencing Kits have provided us with quick workflows, full-length quantitative transcripts, and eased our data analysis since complex statistical considerations that need to be taken for short-read data, where full-length resolution of genes is difficult to determine, are not necessary.”
in relation to his use of the PCR-cDNA Kit to study the transcriptome of the developing olive fly embryo.
Direct cDNA and PCR-cDNA options
The two new kits now available are Direct cDNA (SQK-DCS109) and PCR-cDNA (SQK-PCS109) Sequencing Kits. In combination with upgrades to the Oxford Nanopore sequencing platforms and software, nanopore cDNA sequencing delivers effective enrichment for full-length transcripts (PCR-cDNA). In the case of the Direct cDNA kit, PCR is not necessary — removing bias, whilst the cDNA- PCR kit enables high throughput from low RNA input (just 1 ng PolyA+ RNA) and provides the option of starting from total RNA. The kits, which require less than 5 hours sample preparation time end-to-end, with little of this representing hands-on time, are now available to buy in Oxford Nanopore’s store.
The new cDNA kits are available to use on all Oxford Nanopore devices, from the pocket-sized MinION to the benchtop GridION and the high-throughput PromethION. This allows users of any scale to generate very high yields of transcriptomic data for high-resolution novel isoform discovery, identification of low copy number transcripts and de novo sequencing of entire transcriptomes to high coverage. Small, rapid devices such as Flongle are also ideal for targeted cDNA sequencing of specific transcripts.
In addition to cDNA sequencing, Oxford Nanopore also uniquely offers direct RNA analysis kits, allowing users to sequence RNA without the need to convert to cDNA.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Telna Launches New eSIM Solution at MWC Barcelona 201924.2.2019 00:00:00 | Pressemelding
Telna, a vertically integrated Network-as-a-Service (NaaS) provider of global end-to-end connectivity solutions, today is adding eSIM technology to its platform. The new resilient and efficient eSIM architecture will be showcased at Mobile World Congress Barcelona 2019, from February 25th - February 28th at Telna’s booth in Hall 1, Stand 1B80. “eSIM technology is another example of a global trend in digital transformation set to disrupt cellular connectivity,” says Gregory Gundelfinger, CEO of Telna. “Our customers now have access to both Consumer and IoT/M2M eSIM that is bundled with the rest of our software-defined network services.” eSIM is an embedded SIM card, meaning there is no physical SIM card and no physical swapping of SIM cards. It's easy to add data plans and is endorsed by the GSMA. “The virtualization of the SIM card removes one of the largest barriers when switching between networks, the physical SIM card,” says Gundelfinger. The Telna eSIM allows users to access their
Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00 | Pressemelding
Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00 | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te
Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00 | Pressemelding
Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented
Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00 | Pressemelding
Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is
Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00 | Pressemelding
Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of